The purpose of this study is to provide men and women with relapsed/refractory multiple myeloma (RRMM) expanded access to the antibody-drug conjugate belantamab mafodotin.

This study is open to those who are either enrolled in the BLENREP REMS (Risk Evaluation and Mitigation Strategy) program, or who have RRMM refractory to immunomodulators (IMID), proteasome inhibitors (PI), and an anti-CD38 antibody, and no suitable alternative treatment options.

The purpose of this study is to learn about changes in brain function, thoughts, feelings, and behavior that occur during treatment for depression and suicidal ideation.

Suicidality in mid- and late life is characterized with abnormalities in the Positive Valence System (PVS). The aim of the study is to examine if exposure to meaningful social rewards during psychotherapy engages PVS circuitry and improves mid- and late-life suicidality among depressed older adults.

This is a research study to evaluate the safety and tolerability of an experimental drug called TVB-2640 in combination with Enzalutamide for men with metastatic castration resistant prostate cancer (mCRPC) whose disease has progressed while taking androgen-deprivation therapy (ADT). ADT is the primary treatment method for mCRPC. This study will find the highest dose of TVB-2640 that can be given with Enzalutamide without causing severe side effects.

The overall goal of this study is to compare the effects, good and/or bad of the study drugs brentuximab vedotin and nivolumab (Bv-NIVO) against the standard therapy of chemotherapy with or without radiation for people with Hodgkin Lymphoma (HL) to find out which is better.

Treatment with brentuximab vedotin and nivolumab (Bv-NIVO) is considered investigational, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

This clinical trial is for adults who have advanced and metastatic castrate resistant prostate cancer (mCRPC).
   
The purpose of this study is to test new compounds (64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA) as possible treatment for metastatic castrate resistant prostate cancer (mCRPC), an advanced form of prostate cancer.
   

The purpose of this study is to improve the characterization of breast fatty tissue by performing advanced methods of analyses on ultrasound imaging data obtained from patients scheduled for an ultrasound-guided breast core biopsy.

Study participants will undergo the same ultrasound guided breast core biopsy as standard of care. There will only be 1 study visit.

After the biopsy is completed, participants will be followed for a period of up to 12 months with routine standard of care clinical follow up. 

The purpose of this study is to study the safety and effects of two new immunotherapies aimed at achieving and maintaining tumor shrinkage in patients with non-microsatellite stable colorectal cancer without liver metastases.

Botensilimab (also known as AGEN1181) and balstilimab (also known as AGEN2034) are both experimental drugs, which means that neither have been approved by the U.S. Food and Drug Administration (FDA).

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with multiple myeloma (MM) who have had an autologous hematopoietic stem cell transplant (AHCT) and have already received lenalidomide as maintenance therapy.
   
The study drug iberdomide is designed to target and destroy proteins that produce myeloma cancer cells. By destroying these proteins, iberdomide may prevent the cancer from returning or getting worse. This research study is being done because currently there is no effective treatment for this type of condition.

This clinical trial is for adult participants 50 years of age or older who are not currently suspected of having cancer and do not have a personal history of invasive solid tumor or hematologic malignancy (blood cancer) within the past 3 years.
   

This clinical trial is for adult participants who have metastatic pancreatic cancer and have been given prior chemotherapy with FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin).